PL2547205T3 - Nowe sposoby do celowania nowotworowych komórek macierzystych - Google Patents

Nowe sposoby do celowania nowotworowych komórek macierzystych

Info

Publication number
PL2547205T3
PL2547205T3 PL11757135.6T PL11757135T PL2547205T3 PL 2547205 T3 PL2547205 T3 PL 2547205T3 PL 11757135 T PL11757135 T PL 11757135T PL 2547205 T3 PL2547205 T3 PL 2547205T3
Authority
PL
Poland
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
PL11757135.6T
Other languages
English (en)
Polish (pl)
Inventor
Chiang Jia Li
David Leggett
Youzhi Li
Wei Li
Original Assignee
1Globe Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co., Ltd. filed Critical 1Globe Biomedical Co., Ltd.
Publication of PL2547205T3 publication Critical patent/PL2547205T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11757135.6T 2010-03-19 2011-03-21 Nowe sposoby do celowania nowotworowych komórek macierzystych PL2547205T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
PL2547205T3 true PL2547205T3 (pl) 2024-07-08

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11757135.6T PL2547205T3 (pl) 2010-03-19 2011-03-21 Nowe sposoby do celowania nowotworowych komórek macierzystych

Country Status (18)

Country Link
US (2) US9730909B2 (en:Method)
EP (1) EP2547205B1 (en:Method)
JP (1) JP2013522326A (en:Method)
CN (1) CN103025159A (en:Method)
AU (1) AU2011227023B2 (en:Method)
BR (1) BR112012023660B8 (en:Method)
CA (2) CA2793527A1 (en:Method)
DK (1) DK2547205T3 (en:Method)
ES (1) ES2987670T3 (en:Method)
FI (1) FI2547205T3 (en:Method)
HR (1) HRP20240658T1 (en:Method)
LT (1) LT2547205T (en:Method)
PL (1) PL2547205T3 (en:Method)
RS (1) RS65536B1 (en:Method)
RU (1) RU2591823C2 (en:Method)
SI (1) SI2547205T1 (en:Method)
SM (1) SMT202400193T1 (en:Method)
WO (1) WO2011116399A1 (en:Method)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2200431T1 (sl) 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
NZ712826A (en) * 2010-03-19 2017-03-31 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
KR20150139955A (ko) * 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
CN109867647A (zh) 2014-02-07 2019-06-11 北京强新生物科技有限公司 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐
DK3153508T3 (da) * 2014-06-09 2020-05-18 Kyoto Pharma Ind Naphthofuranderivater til anvendelse som anticancermidler
EA201792287A1 (ru) 2015-04-17 2018-03-30 Бостон Биомедикал, Инк. Способы лечения рака
MX2017013359A (es) 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
HK1245632A1 (zh) 2015-06-03 2018-08-31 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用於治疗癌症的免疫治疗剂
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
SG11202008686TA (en) * 2018-03-08 2020-10-29 Exxonmobil Res & Eng Co Spirocentric compounds and polymers thereof
CN120168498A (zh) 2018-10-12 2025-06-20 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
AU2736400A (en) 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
DE60014928T2 (de) 1999-08-02 2006-03-09 F. Hoffmann-La Roche Ag Retinoide zur behandlung von emphysem
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
BR0214571A (pt) * 2001-11-29 2006-05-30 Therakos Inc métodos para pré-tratar um indivìduo com fotoférese extracorporal e/ou células apoptóticas
DK1344533T3 (da) 2002-03-15 2007-01-08 Natimmune As Farmaceutiske præparater, der omfatter mannosebindende lectin
EP1551392A4 (en) 2002-09-17 2006-09-20 Arqule Inc NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
EP2487156B1 (en) 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
EP1853242A4 (en) 2005-02-25 2009-11-18 Univ Michigan LOW MOLECULAR STAT3 INHIBITORS AND THEIR USES
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
AU2007234455B2 (en) 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
SI2200431T1 (sl) 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
NZ712826A (en) * 2010-03-19 2017-03-31 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells

Also Published As

Publication number Publication date
EP2547205B1 (en) 2024-03-20
RU2591823C2 (ru) 2016-07-20
BR112012023660A2 (pt) 2015-09-15
JP2013522326A (ja) 2013-06-13
RS65536B1 (sr) 2024-06-28
AU2011227023A1 (en) 2012-09-27
AU2011227023B2 (en) 2015-05-28
US20130028944A1 (en) 2013-01-31
RU2012144420A (ru) 2014-04-27
CA2946890A1 (en) 2011-09-22
SI2547205T1 (sl) 2024-08-30
EP2547205A1 (en) 2013-01-23
LT2547205T (lt) 2024-06-10
FI2547205T3 (fi) 2024-05-27
DK2547205T3 (da) 2024-05-27
SMT202400193T1 (it) 2024-07-09
ES2987670T3 (es) 2024-11-15
BR112012023660B1 (pt) 2021-05-18
CA2793527A1 (en) 2011-09-22
BR112012023660B8 (pt) 2021-05-25
CN103025159A (zh) 2013-04-03
US20170319537A1 (en) 2017-11-09
EP2547205A4 (en) 2013-08-14
HRP20240658T1 (hr) 2024-08-16
WO2011116399A1 (en) 2011-09-22
US9730909B2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
PL2547205T3 (pl) Nowe sposoby do celowania nowotworowych komórek macierzystych
IL220756A0 (en) Herbicide-tolerant plants
IL225635A (en) Device for cell culture with internal tools
PT2785834T (pt) Composição de células estaminais melhorada
PT2547205T (pt) Novos métodos para atingir células estaminais cancerígenas
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
IL255309A0 (en) Reprogramming of cancer cells
HUE038864T2 (hu) Herbicid-toleráns növények
EP2760996A4 (en) SOMATIC STEM CELLS
GB201012590D0 (en) Methods for diagnosing cancer
WO2011116344A9 (en) Targeting cancer stem cells
EP2533789A4 (en) METHOD FOR IMPROVING THE FUNCTIONALITY OF SPERM
GB201007944D0 (en) Methods
LT3536334T (lt) Vakcina nuo vėžio, nukreipta į vėžines kamienines ląsteles
PL2568796T3 (pl) Półzawieszany pług obracalny
WO2012106368A9 (en) Methods for inhibiting prostate cancer
GB201011367D0 (en) Methods
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells
HUE044196T2 (hu) Sejtterápia